Background
Methods
Study design
Glycoprotein ELISA (gpELISA)
ELISPOT assay
Safety
Statistical analysis
Results
Baseline characteristics
HSCT 2–5 yr (n = 26) | HSCT > 5 yr (n = 15) | Chemotherapy (n = 15)c | Healthy (n = 30) | |
---|---|---|---|---|
Median age, yr (IQR) | 60 (55–63) | 58 (53–62) | 64 (57–69) | 61 (57–66) |
Male sex, n (%) | 15 (58) | 9 (60) | 10 (67) | 10 (33) |
HSCT indication, n (%) | ||||
Leukemia | 11 (42) | 4 (27) | 14 (93) | N/A |
Lymphoma | 2 (8) | 7 (47) | ||
Multiple myeloma | 6 (23) | 1 (6.5) | ||
Myelodysplastic syndrome | 4 (15) | 2 (13) | ||
Othersa | 3 (12) | 1 (6.5) | 1 (7) | |
Type of HSCT, n (%) | ||||
Allogeneic | 20 (77) | 9 (60) | N/A | N/A |
Autologous | 6 (23) | 6 (40) | ||
Time between HSCT or last chemo and the study date, mo (IQR) | 35 (25–44) | 87 (66–91) | 65 (23–104) | N/A |
Previous shingles history, yes, n (%) | 12 (46) | 9 (60) | 6 (40) | 0 (0) |
Shingles within 2 yrs after HSCT or last chemo, n (%) | 9/12 (75) | 6/9 (67) | 5/6 (83) | N/A |
Median years from shingles to the study date (IQR) | 3 (1.5–4)b | 5 (5–7) | 2.5 (1.3–6) | N/A |
Humoral immune responses
Cellular immune responses
Safety
HSCT 2–5 yr (n = 26) | HSCT > 5 yr (n = 15) | Chemotherapy (n = 15) | Healthy (n = 30) | |
---|---|---|---|---|
Any adverse events, n (%) | 5 (19.2) | 3 (20.0) | 2 (13.3) | 0 (0) |
Local adverse events, n (%) | 4 (15.4) | 2 (13.3) | 1 (6.6) | 0 (0) |
Pain or tenderness | 3 (11.5) | 2 (13.3) | 1 (6.6) | 0 (0) |
Redness | 3 (11.5) | 2 (13.3) | 1 (6.6) | 0 (0) |
Induration or edema | 1 (3.8) | 2 (13.3) | 1 (6.6) | 0 (0) |
Itching | 3 (11.5) | 2 (13.3) | 1 (6.6) | 0 (0) |
Systemic adverse events, n (%) | 3 (11.5) | 1 (6.6) | 1 (6.6) | 0 (0) |
Headache | 1 (3.8) | 1 (6.6) | 0 (0) | 0 (0) |
Myalgia or arthralgia | 3 (11.5) | 1 (6.6) | 0 (0) | 0 (0) |
Fatigue | 3 (11.5) | 0 (0) | 1 (6.6) | 0 (0) |
Fever | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Systemic allergic reaction | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Nausea or vomiting | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Diarrhea | 0 (0) | 0 (0) | 0 (0) | 0 (0) |